Abstract
An increasing number of studies have shown a critical role for the membrane attack complex, synthesized on activation of the terminal pathway of the complement system, in causing demyelination and neuronal death in neurodegeneration. The aim of this study was to develop a strategy to increase the resistance of neurons to complement damage by modulating the expression of membrane complement regulatory protein CD59, the only inhibitor of the terminal pathway of the complement cascade. We exploited our recent finding that CD59 expression is regulated by the neural-restrictive silencer factor (REST) and designed a novel REST-derived peptide (REST5) containing the nuclear localization domain of the wild-type protein. The effect of REST5 and the mechanism by which it modulates CD59 expression were modelled in neuroblastoma cells transfected with expression constructs, and then confirmed in human neurons differentiated from neural progenitor cells. REST5 increased the expression of CD59 in neurons by fivefold and protected them from complement-mediated lysis spontaneously triggered by neurons. As a source of complement, we used either human serum or conditioned medium from primary human oligodendroglia. This study brings new insight into immunopharmacological research that may serve to inhibit neuronal death triggered by the terminal pathway of complement activation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Walport MJ . Advances in immunology: complement (first of two parts). N Engl J Med 2001; 344: 1058–1066.
Gasque P, Neal J, Singhrao S, McGreal E, Dean Y, Van B et al. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol 2002; 25: 1–17.
Barnum S . Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 1995; 6: 132–146.
Silva C, Rio M, Cruz C . Local immunoglobulin synthesis and blood-brain barrier assessment in subacute sclerosing panencephalitis. Eur Neurol 1985; 24: 128–133.
Gasque P, Fontaine M, Morgan B . Complement expression in human brain—biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 1995; 154: 4726–4733.
Gasque P, Julen N, Ischenko A, Picot C, Mauger C, Chauzy C et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992; 149: 1381–1387.
Morgan B, Gasque P . Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 1997; 107: 1–7.
Hosokawa M, Klegeris A, Maguire J, McGeer P . Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia 2003; 42: 417–423.
Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G et al. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 2002; 1: 499–509.
Kolev M, Ruseva M, Harris C, Morgan B, Donev R . Implication of complement system and its regulators in Alzheimer's disease. Curr Neuropharmacol 2009; 7: 1–8.
Osaka H, Mukherjee P, Aisen P, Pasinetti G . Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999; 73: 303–311.
Pasinetti G . Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging 1996; 17: 707–716.
Mead R, Singhrao S, Neal J, Lassmann H, Morgan B . The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002; 168: 458–465.
Mead R, Neal J, Griffiths M, Linington C, Botto M, Lassmann H et al. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab Invest 2004; 84: 21–28.
Vedeler C, Ulvestad E, Bjørge L, Conti G, Williams K, Mørk S et al. The expression of CD59 in normal human nervous tissue. Immunology 1994; 82: 542–547.
Pasinetti G, Johnson S, Oda T, Rozovsky I, Finch C . Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J Comp Neurol 1994; 339: 387–400.
Singhrao S, Neal J, Rushmere N, Morgan B, Gasque P . Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000; 157: 905–918.
Gasque P, Morgan B . Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology 1996; 89: 338–347.
Yang L, Li R, Meri S, Rogers J, Shen Y . Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci 2000; 20: 7505–7509.
Donato R, Miljan E, Hines S, Aouabdi S, Pollock K, Patel S et al. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci 2007; 8: 36.
Harris C, Williams A, Linton S, Morgan B . Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol 2002; 129: 198–207.
Donev RM, Cole DS, Sivasankar B, Hughes TR, Morgan BP . p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res 2006; 66: 2451–2458.
Donev R, Gray L, Sivasankar B, Hughes T, van den Berg C, Morgan B . Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res 2008; 68: 5979–5987.
Shimojo M, Hersh LB . REST/NRSF-interacting LIM domain protein, a putative nuclear translocation receptor. Mol Cel Biol 2003; 23: 9025–9031.
Shimojo M, Lee JH, Hersh LB . Role of zinc finger domains of the transcription factor neuron-restrictive silencer factor/repressor element-1 silencing transcription factor in DNA binding and nuclear localization. J Biol Chem 2001; 276: 13121–13126.
Harris C, Hughes C, Williams A, Goodfellow I, Evans D, Caterson B et al. Generation of anti-complement ‘prodrugs’: cleavable reagents for specific delivery of complement regulators to disease sites. J Biol Chem 2003; 278: 36068–36076.
Lee K, Luu N, Kaneski C, Schiffmann R, Brady R, Murray G . Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain. Biochem Biophys Res Commun 2005; 337: 701–707.
Westbrook T, Hu G, Ang X, Mulligan P, Pavlova N, Liang A et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008; 452: 370–374.
Johnson D, Mortazavi A, Myers R, Wold B . Genome-wide mapping of in vivo protein-DNA interactions. Science 2007; 316: 1497–1502.
Weissman A . How much REST is enough? Cancer Cell 2008; 13: 381–383.
Singhrao S, Neal J, Rushmere N, Morgan B, Gasque P . Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest 1999; 79: 1247–1259.
Lucas S, Rothwell N, Gibson R . The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147 (Suppl 1): S232–S240.
Maier M, Peng Y, Jiang L, Seabrook T, Carroll M, Lemere C . Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 2008; 28: 6333–6341.
Acknowledgements
This study was funded by the Medical Research Council New Investigator Grant G0700102 (RM Donev) and by the Wellcome Trust Programme Grant 068590 (BP Morgan).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kolev, M., Tediose, T., Sivasankar, B. et al. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics J 10, 12–19 (2010). https://doi.org/10.1038/tpj.2009.52
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2009.52
Keywords
This article is cited by
-
Predictive value of soluble CD59 for poor 28-day neurological prognosis and all-cause mortality in patients after cardiopulmonary resuscitation: a prospective observatory study
Journal of Intensive Care (2023)
-
Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
Journal of Neuroinflammation (2018)
-
CD59 mediates cartilage patterning during spontaneous tail regeneration
Scientific Reports (2015)
-
What does complement do in Alzheimer’s disease? Old molecules with new insights
Translational Neurodegeneration (2013)
-
Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice
Journal of Neuroinflammation (2010)